Calcineurin-inhibitor induced pain syndrome in a lung transplant patient

Sahay, Sandeep; McBennett, Kimberly; Sheers, Titus

doi:10.1111/tri.12103

Cited by 10 publications

(14 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When discussing pain after SOT it is necessary to address calcineurin inhibitor‐induced pain syndrome (CIPS), a severely disabling complication after SOT established by Grotz et al., 2001 . The overall incidence of the syndrome ranges from 1 to 17% in SOT‐recipients . There are few studies of CIPS among lung transplant recipients.…”

Section: Introductionmentioning

confidence: 99%

“…However, it is clinically reasonable to believe that CIPS might cause pain, especially in the feet, also after lung transplantation. Those that are available take the form of either a case study or the lung recipients are part of a group of other transplant recipients where calcineurin inhibitor‐induced headache was reported among 74 patients following lung, liver or bone marrow transplantation. The usual onset occurs 1‐3 months after the introduction of calcineurin inhibitors (CIs), and the syndrome presents as symmetric bilateral pain in the lower extremities involving the bones of the feet, ankles and knees.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pain, fatigue and well‐being one to five years after lung transplantation – a nationwide cross‐sectional study

Forsberg

Claëson

Dahlman

et al. 2017

Scandinavian Caring Sciences

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Pain, fatigue and well‐being one to five years after lung transplantation – a nationwide cross‐sectional study

Forsberg

Claëson

Dahlman

et al. 2017

Scandinavian Caring Sciences

View full text Add to dashboard Cite

show abstract

“…3 Since then it has also been defined in other solid organ and bone marrow transplant patients. [7][8][9] Its incidence is 1% to 2%, more common in females, and the symptoms can manifest at any time between 3 weeks and 8 years after transplantation. 2,9 Although more common in feet and lower extremities, cases with asymmetric presentation and upper extremity involvement have also been reported.…”

Section: Discussionmentioning

confidence: 99%

Pregabalin

Taşoğlu¹,

Gökcan²,

Demir³

et al. 2016

Prog Transpl

View full text Add to dashboard Cite

Tacrolimus and cyclosporin are calcineurin inhibitors (CIs) commonly used in organ transplants. These agents rarely cause a severe, debilitating pain syndrome of especially lower extremities, known as CI pain syndrome (CIPS). Although the pathogenesis is not well understood, neuropathic pain mechanisms have started to be discussed in the recent literature. Here, presenting a 48-year-old male with CIPS who recovered after pregabalin 150 mg twice daily, we aimed to emphasize the importance of this syndrome and offer a new approach for the treatment. This is the first report in the literature where pregabalin is demonstrated to be effective in CIPS.

show abstract

“…4 Likewise, in lung transplantation the source of pain is multifactorial and related to preexisting pain conditions, calcineurin-inhibitors, and pain at incision and thoracostomy tube sites. 2,5,6 Lung transplant patients are quite heterogeneous, varying significantly in age, comorbid conditions, indication for transplantation, and risk factors for pain. Nationally, there has been an increase in the number of lung transplants performed, with concomitant increases in the medical and surgical complexity of transplant recipients.…”

Section: Introductionmentioning

confidence: 99%

Patient-Reported Chronic Pain Outcomes After Lung Transplantation

Klinger

Cunniff

Mamoun

et al. 2019

Semin Cardiothorac Vasc Anesth

View full text Add to dashboard Cite

Chronic pain after lung transplantation is a significant concern, in particular given the heterogeneity of the patient population and the challenges of achieving adequate pain control amid concerns related to complex immunosuppressant regimens and the possibility of respiratory depression. We undertook a patient-reported outcomes (PRO) survey administered via our electronic health care portal to examine the postoperative incisional pain prevalence in a cohort of lung transplant recipients at a single, high-volume center where bilateral thoracosternotomy is the preferred surgical approach. The Patient Reported Outcomes Measurement Information System (PROMIS) Global Health and Pain Intensity short forms were sent to a total of 173 lung transplant recipients who were more than 2 months postsurgery at the time of the study. A total of 64 patients responded to both PROMIS surveys (response rate 38%). In the cohort of survey respondents, we observed a chronic pain incidence of 58% after lung transplantation (median pain score 1/10) and an overall good quality of life score (median score 4/5); however, only 9.4% reported moderate-severe pain (pain score ≥5/10). Survey nonrespondents had higher rates of pretransplant opioid and psychiatric medication use compared with respondents. In this study, we demonstrated the feasibility of using an electronic PRO survey for assessing postoperative pain outcomes after lung transplantation. However, measuring pain outcomes using this type of tool highlights issues of response rate and potential selection bias. Larger studies are needed to adequately assess the risk and predictors of chronic pain after lung transplantation and its impact on quality of life.

show abstract

Calcineurin-inhibitor induced pain syndrome in a lung transplant patient

Cited by 10 publications

References 13 publications

Pain, fatigue and well‐being one to five years after lung transplantation – a nationwide cross‐sectional study

Pain, fatigue and well‐being one to five years after lung transplantation – a nationwide cross‐sectional study

Pregabalin

Patient-Reported Chronic Pain Outcomes After Lung Transplantation

Contact Info

Product

Resources

About